Table 2.
Cyclic Peptide Sequence | Conjugate Polymer | Drug | Tube Size (μm) | Drug Delivery | Reference | ||||||
---|---|---|---|---|---|---|---|---|---|---|---|
| |||||||||||
IC50 (μM) | |||||||||||
| |||||||||||
A2780 | A2780cis | MCF-7 | MCF-7/ADR | BEL7402 | HeLa | S180 | |||||
None | None | 5-Fluorouracil | ND | ND | ND | ND | ND | 596 | 1460 | 1790 | [55] |
Gln-(D-Leu-Trp)4-D-Leu | None | 5-Fluorouracil | ND | ND | ND | ND | ND | 241 | 819 | 389 | |
None | None | Doxorubicin | ND | ND | ND | 0.53 ± 0.05 | 4.21 ± 0.65 | ND | ND | ND | [57] |
Gln-D-Ala-Glu-D-Ala-Gln-D-Ala-Cys-D-Ala | PEG | Doxorubicin | Length: 0.05–0.08 Width: 0.01 |
ND | ND | 0.16 ± 0.03 | 0.84 ± 0.04 | ND | ND | ND | |
None | None | Ruthenium | ND | 271 | 266 | ND | ND | ND | ND | ND | [58] |
(Azido-Lys-D-Leu-Trp-D-Leu)2 | HEA-co-CEMA | Ruthenium | Length: 0.2–0.5 | 15 | 22 | ND | ND | ND | ND | ND | |
None | None | Iridium | ND | 0.95 ± 0.03 | ND | ND | ND | ND | ND | ND | [56] |
None | HPMA-co-PUEMA | Iridium | ND | 1.80 ± 0.09 | ND | ND | ND | ND | ND | ND | |
(D-Leu-Lys-D-Leu-Trp)2 | HPMA-co-PUEMA | Iridium | Length: 0.022 ± 0.001 | 0.61 ± 0.02 | ND | ND | ND | ND | ND | ND | |
| |||||||||||
Cyclic Peptide Sequence | Conjugate Polymer | Gene | Tube Size (μm) | Gene Delivery | Reference | ||||||
| |||||||||||
Cell | Aimal | Route | Expression Organ | ||||||||
| |||||||||||
(D-Ala-Lys)4 | None | pF143-GFP | Width: 0.01–0.4 | HeLa HEK-293 |
None | None | None | [60] | |||
D-Trp-Tyr | None | pCMV-LacZ | Length: 1–20 | None | Mice | Oral | Stomach Duodeum |
[32] | |||
pCMV-hRluc | Width: 0.1–0.8 | Liver Kidney |
|||||||||
D-Trp-Tyr | None | pCMV-bcl-xL-eGFP | Length: 1.4 ± 0.8 | None | Mice | Eye | Cornea | [61] | |||
CAP3 pRFP-C-RS | Width: 0.26 ± 0.06 |
IC50: half-inhibition concentration; HPMA: Hydroxypropyl methacrylamide; PUEMA: 2-(3-(Pyridin-4-ylmethyl)ureido)ethyl)methacrylate; HEA: 2-Hydroxyethyl acrylate; CEMA: 2-Chloroethyl meth-acrylate; ND: Non-detected;